Vaxcyte, Inc. (PCVX)
NASDAQ: PCVX · Real-Time Price · USD
58.25
-1.88 (-3.13%)
Mar 5, 2026, 4:00 PM EST - Market closed
Vaxcyte Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Cost of Revenue | - | - | 75 | 23 | - | |
| Gross Profit | - | - | -75 | -23 | - | |
| Selling, General & Admin | 129.37 | 92.9 | 60.7 | 39.81 | 25.26 | |
| Research & Development | 794.31 | 476.64 | 332.34 | 169.45 | 78.41 | |
| Operating Expenses | 923.68 | 569.55 | 393.04 | 209.26 | 103.67 | |
| Operating Income | -923.68 | -569.55 | -468.04 | -232.26 | -103.67 | |
| Interest Expense | - | - | - | -0 | -0.01 | |
| Interest & Investment Income | 119.72 | 109.99 | 62.91 | 8.36 | 0.34 | |
| Currency Exchange Gain (Loss) | - | - | - | - | 1.67 | |
| Other Non Operating Income (Expenses) | 37.33 | -4.38 | 2.87 | 0.42 | 1.59 | |
| EBT Excluding Unusual Items | -766.63 | -463.93 | -402.27 | -223.49 | -100.08 | |
| Gain (Loss) on Sale of Investments | - | - | - | - | 0 | |
| Pretax Income | -766.63 | -463.93 | -402.27 | -223.49 | -100.08 | |
| Net Income | -766.63 | -463.93 | -402.27 | -223.49 | -100.08 | |
| Net Income to Common | -766.63 | -463.93 | -402.27 | -223.49 | -100.08 | |
| Shares Outstanding (Basic) | 136 | 122 | 97 | 65 | 52 | |
| Shares Outstanding (Diluted) | 136 | 122 | 97 | 65 | 52 | |
| Shares Change (YoY) | 11.55% | 25.57% | 49.75% | 24.95% | 75.73% | |
| EPS (Basic) | -5.63 | -3.80 | -4.14 | -3.44 | -1.93 | |
| EPS (Diluted) | -5.63 | -3.80 | -4.14 | -3.44 | -1.93 | |
| Free Cash Flow | -712.55 | -571.79 | -364.67 | -176.44 | -127.95 | |
| Free Cash Flow Per Share | -5.24 | -4.69 | -3.75 | -2.72 | -2.46 | |
| EBITDA | -907.28 | -562.54 | -464.89 | -229.42 | -101.87 | |
| D&A For EBITDA | 16.4 | 7 | 3.16 | 2.83 | 1.8 | |
| EBIT | -923.68 | -569.55 | -468.04 | -232.26 | -103.67 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.